A U.S. cannabis company has made an unsolicited bid to acquire Aurora Cannabis Inc., a company based in Edmonton. Aurora has responded by forming a special committee to evaluate the offer. Curaleaf Holdings Inc., based in Stamford, Conn., announced its intentions to purchase all shares of Aurora, aiming to create a combined cannabis entity operating in 17 countries across Europe, North America, and other global markets.
Curaleaf’s efforts to engage in private negotiations with Aurora’s leadership were unsuccessful, leading to the public disclosure of its proposal. Despite sending letters on June 23 and July 7 outlining the acquisition plans, Aurora claimed that only the latter letter included proposed financial terms. It also denied Curaleaf’s assertion that Aurora rejected the offer outright, stating that discussions were ongoing as of July 24.
Curaleaf’s proposal includes paying Aurora shareholders $4 US per share, along with an additional $0.75 US in cash for each Aurora share. Aurora, however, expressed reservations about the offer, indicating that it may undervalue the long-term potential of its business. TD Cowen analysts echoed this sentiment, suggesting that Aurora’s market leadership in medical cannabis and its strong balance sheet could lead to greater value creation over time.
Both companies have highlighted the potential benefits of a merger, citing synergies in global distribution, cultivation, and manufacturing capacities. The proposed takeover is expected to result in significant cost savings and increased exposure to favorable U.S. regulatory trends. Despite the interest shown by Curaleaf, Aurora emphasized that a deal is not guaranteed and that business operations will continue as usual while the special committee evaluates the proposal.
